Continuous Infusion of Terlipressin in Septic Shock
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether: A)the continuous infusion ultra-low dose
of terlipressin (1.3 micrograms/kg/h) is able to stabilize hemodynamic in patients with
septic shock, reducing the risk of adverse effects related to the bolus dose.B)the continuous
infusion ultra-low dose of terlipressin may be use in lieu of vasopressin.